Table 6 ABG and spirometry before and after 2 months of IS use and medical treatment among group I (N=20)
Studied variables | Group I | Test of significance | P value | |
|---|---|---|---|---|
Before | After 2 months | |||
PaO2 (mmHg) | ||||
Mean±SD | 61.8±3.36 | 65.5±7.63 | Z | 0.002** |
Median | 61.5 | 66.0 | 3.13 | |
Range | 55.0–67.0 | 37.0–79.0 | ||
PaCO2(mmHg) | ||||
Mean±SD | 46.5±6.07 | 43.6±7.03 | Z | 0.003** |
Median | 48.0 | 44.0 | 3.01 | |
Range | 32.0–57.0 | 31.0–67.0 | ||
FVC (%) | ||||
Mean±SD | 79.6±11.4 | 77.2±15.0 | Z | 0.220 |
Median | 80.0 | 81.5 | 1.22 | |
Range | 52.0–107.0 | 32.0–107.0 | ||
FEV1/FVC | ||||
Mean±SD | 56.6±10.7 | 60.2±10.9 | Z | 0.001** |
Median | 59.0 | 63.5 | 3.92 | |
Range | 23.0–66.0 | 30.0–69.0 | ||
PEFR (%) | ||||
Mean±SD | 27.2±7.56 | 31.9±8.11 | Z | 0.001** |
Median | 25.5 | 32.0 | 3.73 | |
Range | 17.0–51.0 | 20.0–52.0 | ||
mMRC dyspnea scale | ||||
Scale 2 | 2 (10.0) | 6 (30.0) | X2 | 0.276 |
Scale 3 | 16 (80.0) | 12 (60.0) | 2.571 | |
Scale 4 | 2 (10.0) | 2 (10.0) | ||